Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Rating) Director Anne Oriordan sold 466 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $148.95, for a total value of $69,410.70. Following the completion of the sale, the director now directly owns 9,245 shares in the company, valued at approximately $1,377,042.75. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
JAZZ stock opened at $146.49 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.06 and a current ratio of 3.39. The business has a fifty day simple moving average of $158.32 and a 200-day simple moving average of $142.76. Jazz Pharmaceuticals plc has a 52 week low of $117.64 and a 52 week high of $189.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The specialty pharmaceutical company reported $3.73 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.73. The business had revenue of $813.72 million during the quarter, compared to the consensus estimate of $853.73 million. Jazz Pharmaceuticals had a positive return on equity of 22.45% and a negative net margin of 13.63%. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.42 EPS. Research analysts expect that Jazz Pharmaceuticals plc will post 14.73 EPS for the current year.
A number of equities research analysts recently issued reports on JAZZ shares. Cowen upped their target price on Jazz Pharmaceuticals from $200.00 to $225.00 in a research note on Thursday, May 5th. Truist Financial increased their price target on Jazz Pharmaceuticals from $180.00 to $200.00 in a research note on Thursday, January 20th. Piper Sandler reduced their price target on Jazz Pharmaceuticals from $197.00 to $193.00 in a research note on Thursday, May 5th. The Goldman Sachs Group lowered Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $202.00 to $196.00 in a research note on Wednesday, April 6th. Finally, Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $216.00 to $214.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 2nd. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $206.47.
Jazz Pharmaceuticals Company Profile (Get Rating)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
- Get a free copy of the StockNews.com research report on Jazz Pharmaceuticals (JAZZ)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.